Patterns of curative treatment for non-small cell lung cancer in New South Wales, Australia

被引:2
作者
Batumalai, Vikneswary [1 ,2 ]
Descallar, Joseph [1 ]
Gabriel, Gabriel [1 ]
Delaney, Geoff P. [1 ,3 ]
Oar, Andrew [4 ]
Barton, Michael B. [1 ,3 ]
Vinod, Shalini K. [1 ,3 ]
机构
[1] Univ New South Wales, Collaborat Canc Outcomes Res & Evaluat, Ingham Inst Appl Med Res, South Western Clin Sch, Sydney, NSW, Australia
[2] GenesisCare, Bldg 1&11,41-43 Bourke Rd, Alexandria, NSW 2015, Australia
[3] South Western Sydney Local Hlth Dist, Dept Radiat Oncol, Sydney, NSW, Australia
[4] Gold Coast Univ Hosp, Icon Canc Ctr, Gold Coast, Australia
关键词
curative; non-small cell lung cancer; practice patterns; radiotherapy; surgery; RADIOTHERAPY; CARE; COMORBIDITY; DISPARITIES; SURGERY; IMPACT; AGE;
D O I
10.1111/ajco.13811
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction There is a lack of large population-based studies examining patterns of curative treatment for non-small cell lung cancer (NSCLC) in Australia. This study aimed to evaluate the utilization of curative treatment for NCSLC at a population level and identify factors associated with its use in New South Wales (NSW), Australia. Methods Patients diagnosed with localized or locoregional NSCLC between 2009 and 2014 were identified from the NSW Central Cancer Registry. Curative treatment was defined as surgery or radiotherapy with a 45 Gy minimum dose. Univariate and multivariable analyses were performed to investigate factors associated with the receipt of curative treatment. A Cox proportional-hazards regression model was used to analyze the factors associated with 2-year overall survival (OS). Results Of the 5722 patients diagnosed with NSCLC in the study period, 3355 (59%) patients received curative treatment and 2367 (41%) patients did not receive curative treatment. The receipt of curative treatment was significantly associated with younger patients, female gender, localized disease, and Charlson Comorbidity Index (CCI) = 0. The use of curative treatment increased significantly over time from 2009 (55%) to 2014 (63%) and varied significantly from 24% to 70% between local health districts (LHDs) of residence. Younger age, female gender, localized disease, CCI = 0, and overseas country of birth were significantly associated with 2-year OS. The 2-year OS significantly improved from 70% in 2009 to 77% in 2014 for patients who received curative treatment. Conclusion The use of curative treatment for patients with potentially curable NSCLC was low at 59%. However, the use of curative treatment and survival have increased over time. Significant variation was noted in the use of curative treatment between LHDs.
引用
收藏
页码:E149 / E159
页数:11
相关论文
共 50 条
  • [41] Postoperative radiotherapy for non-small cell lung cancer
    Burdett, Sarah
    Rydzewska, Larysa
    Tierney, Jayne
    Fisher, David
    Parmar, Mahesh K. B.
    Arriagada, Rodrigo
    Pignon, Jean Pierre
    Le Pechoux, Cecile
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (09):
  • [42] Management of brain metastases from non-small cell lung cancer
    Baykara, Meltem
    Kurt, Gokhan
    Buyukberber, Suleyman
    Demirci, Umut
    Ceviker, Necdet
    Algin, Efnan
    Coskun, Ugur
    Aykol, Sukru
    Emmez, Hakan
    Ozet, Ahmet
    Benekli, Mustafa
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (04) : 915 - 921
  • [43] Influence of timeliness and receipt of first treatment on geographic variation in non-small cell lung cancer mortality
    Wah, Win
    Stirling, Rob G.
    Ahern, Susannah
    Earnest, Arul
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (08) : 1828 - 1838
  • [44] Patterns of care for stage III non-small cell lung cancer in Australia
    Parente, Phillip
    Chan, Bryan A.
    Hughes, Brett G. M.
    Jasas, Kevin
    Joshi, Rohit
    Kao, Steven
    Hegi-Johnson, Fiona
    Hui, Rina
    McLaughlin-Barrett, Sara
    Nordman, Ina
    Stone, Emily
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (03) : 93 - 100
  • [45] Comorbidities with non-small cell lung cancer: Is there an interdisciplinary consensus needed to qualify patients for surgical treatment?
    Lembicz, Marta
    Gabryel, Piotr
    Brajer-Luftmann, Beata
    Dyszkiewicz, Wojciech
    Batura-Gabryel, Halina
    ANNALS OF THORACIC MEDICINE, 2018, 13 (02) : 101 - 107
  • [46] Diagnosis and treatment of lung cancer - Non-small cell lung cancer, small cell lung cancer and carcinoids
    End A.
    European Surgery, 2006, 38 (1) : 45 - 53
  • [47] Stage III Non-Small-Cell Lung Cancer Population-Based Patterns of Treatment in British Columbia, Canada
    Vinod, Shalini K.
    Wai, Elaine
    Alexander, Cheryl
    Tyldesley, Scott
    Murray, Nevin
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : 1155 - 1163
  • [48] STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): PATTERNS OF TREATMENT IN BRITISH COLUMBIA, CANADA
    Vinod, Shalini K.
    Wai, Elaine
    Alexander, Cheryl
    Christie, Jennifer
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S625 - S625
  • [49] Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer
    Di Maio, Massimo
    Costanzo, Raffaele
    Giordano, Pasqualina
    Piccirillo, Maria Carmela
    Sandomenico, Claudia
    Montanino, Agnese
    Carillio, Guido
    Muto, Paolo
    Jones, David R.
    Daniele, Gennaro
    Perrone, Francesco
    Rocco, Gaetano
    Morabito, Alessandro
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (06) : 844 - 851
  • [50] Radical treatment of non-small cell lung cancer during the last 5 years
    McCloskey, Paula
    Balduyck, Bram
    Van Schil, Paul E.
    Faivre-Finn, Corinne
    O'Brien, Mary
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (07) : 1555 - 1564